2780 results about "Methionine biosynthesis" patented technology

A method of thermally processing a tobacco material is provided, the method including the steps of (i) mixing a tobacco material, water, and an additive selected from the group consisting of lysine, glycine, histidine, alanine, methionine, glutamic acid, aspartic acid, proline, phenylalanine, valine, arginine, di- and trivalent cations, asparaginase, saccharides, phenolic compounds, reducing agents, compounds having a free thiol group, oxidizing agents, oxidation catalysts, plant extracts, and combinations thereof, to form a moist tobacco mixture; (ii) heating the moist tobacco mixture at a temperature of at least about 60° C. to form a heat-treated tobacco mixture; and (iii) incorporating the heat-treated tobacco mixture into a tobacco product. Heat-treated tobacco composition prepared according to the method are also provided, such as heat-treated smokeless tobacco composition comprising a tobacco material, water, flavorant, binder, and filler, the heat-treated smokeless tobacco composition having an acrylamide content of less than about 2000 ppb.

The invention relates to an enzymology measuring method and reagent with circular increment technology, applied to measure the content of homeotypic cysteine in the measured sample. The character is: with a circular increment technology, increases the measurement sensitivity, thus it can carries on automatic measurement to the homeotypic cysteine in the sample liquid like normal enzymology diagnosing agent. The homeotypic cysteine in the sample liquid reacts with the S-adenosine-L-methionine repeatedly and circularly under the effect of homeotypic cysteine methyl kinase and adenosine homeotypic cysteine, generates the adenosine, the speed of the adenosine generation is in direct proportion to the homeotypic cysteine in the sample, through the generation speed, the aim to measure the content of the homeotypic cysteine in sample can be achieved.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of systemically administered compositions which include primary amine derivatives of benzoic acid as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering the aldehyde and/or ketone products of lipid peroxidation. Increased levels of lipid peroxidation have been repeatedly demonstrated as a part of the non-enzymatic "inflammatory cascade" process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid (or PABA) is an example of the primary therapeutic agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group that reacts with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods. The carbonyl sequestering agents are used in combination with at least one co-agent so as to produce an additional beneficial physiological effect of an anti-inflammatory nature. Such compositions are administered systemically entirely via the oral route. Co-agents of the present invention include anti-oxidants and free radical trapping compounds (e.g., alpha-tocopherol), compounds having indirect anti-oxidant activity (e.g., selenium), vitamins (e.g., pyridoxine HCl), compounds which facilitate kidney drug elimination (e.g., glycine), metabolites at risk of depletion (e.g., pantothenic acid), sulfhydryl containing chemicals (e.g., methionine), compounds which facilitate glutathione activity (e.g., N-acetylcysteine), and non-absorbable polyamine co-agents (e.g., chitosan).

The five component composition consisting essentially of: (1) Water soluble antioxidant vitamin C or ascorbic acid, or any of its forms or derivatives, or mixtures thereof. (2) Oil soluble antioxidant vitamin E or Alpha-tocophorol, or any of its forms or derivatives, or mixtures thereof. (3) The element selenium, or a chemical (or composition) containing it, or mixtures thereof. The most preferred chemical containing selenium is dimethyl selenide and mixtures thereof. The words "dimethyl selenide" here and hereinafter mean dimethyl selenide and/or it's oxidation products, including dimethyl selenoxide. (4) A sulfur amino acid, in any form, or a sulfur peptide, or a sulfur protein, or any of their derivatives, or mixtures thereof. The mixture of methionine and cysteine, which contains as impurities some seleno-methionine and some selenocysteine, is preferred,-the tripeptide glutathione containing cysteine is also preferred. (5) Another antioxidant, other than vitamin C and other than vitamin E, which is synthetic or natural and water soluble or oil soluble, or a mixture of such antioxidants, or a combination of such forms thereof. The mixtures of butylated hydroxyanisole and ethoxyquin is preferred.

The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.

L-Methionine is produced by culturing a microorganism which is deficient in repressor of L-methionine biosynthesis system and/or enhanced intracellular homoserine transsuccinylase activity is cultured in a medium so that L-methionine should be produced and accumulated in the medium, and collecting the L-methionine from the medium. The microorganism preferably further exhibits reduced intracellular S-adenosylmethionine synthetase activity, L-threonine auxotrophy, enhanced intracellular cystathionine γ-synthase activity and enhanced intracellular aspartokinase-homoserine dehydrogenase II activity. The present invention enables breeding of L-methionine-producing bacteria, and L-methionine production by fermentation.

A microorganism strain suitable for fermentative production of L-methionine and preparable from a starting strain, which comprises increased activity of a yjeH gene product or of a gene product of a yjeH homolog, compared to the starting strain.

Personal care composition comprising at least one hair growth regulating compound selected from the group consisting of glyceryl dilaurate, apigenin, tetrahydrocurcumin, oleanolic acid, azelaic acid, sulforaphane, canavanine, pyridoxal 5-phosphate, phytic acid, tannic acid, grape seed extract, NG-nitro-L-arginine-methyl ester, benzamidine, sodium butyrate, betulinic acid, polyornithine, polyarginine, fisetin, jasmonates, methyl-jasmonate, cis-jasmone, caffeic acid phenethyl ester, delphinidin, ethyl abietate, esculetin, sorbic acid methyl ester, canaline, N-formyl-methionine, N-formyl-alanine, taurine, palmitoyl carnitine, undecanol, undecylenic acid, rutin, fusidic acid, phenyl pyruvic acid, L-isoleucine, phenyl glycine, silibinin, silymarin, L-ascorbic acid-6-palmitate, N-undecylenoyl-L-phenylalanine, and salts, derivatives and mixtures of any of the foregoing; and a dermatologically-acceptable carrier.

The invention relates to a layer foodstuff used for producing health care eggs, consisting of the following components in weight portion: 120 to 160 portions of calcium hydrogen phosphate, 250 to 350 portions of mountain flour, 50 to 60 portions of common salt, 20 to 40 portions of saleratus, 15 to 20 portions of choline, 35 to 40 portions of complex trace elements, 8 to 10 portions of complex vitamins, 10 to 15 portions of lysine, 25 to 30 portions of methionine, 220 to 400 portions of pine needle meal, 1 to 3 portions of bacillus subtilis, 8 to 10 portions of copper sulfate, 2 to 5 portions of phytase, 1 to 5 portions of yeast selenium, 3 to 6 portions of vitamin E, and 250 to 400 portions of Chinese traditional herbal medicine preparation. The invention adds nutritive additives etc. into the foodstuff; therefore the egg laid by the layer contains such beneficial elements as selenium, vitamin E, and is rich in Omega-3 polyunsaturated fatty acid and low in cholesterol.

Polymerase chain reaction primers and methods directed to detecting the EGFR mutant C→T at the position corresponding to base 2369 of EGFR cDNA. The invention provides a PCR primer that hybridizes under suitable PCR conditions to a polynucleotide sequence 5′ in each respective strand to a mutation of an EGFR gene that encodes a substitution of threonine by methionine at position 790 of the EGFR polypeptide. The invention also provides a PCR primer hybridizes to a sequence that includes a mutant T at the position corresponding to base 2369 of EGFR cDNA but not to a second EGFR polynucleotide containing a wild type C. The invention provides several methods and kits for detecting a mutant epidermal growth factor receptor (EGFR) gene in a sample comprising probing the sample with a means for selectively detecting a nucleotide sequence comprising a mutant T at the position corresponding to base 2369 of EGFR cDNA, and identifying that the base at said position is T. These methods and kits are also useful to predict resistance to the therapeutic effects of gefitinib or erlotinib in a subject suffering from or suspected of having a cancer.

A composition of bio-active compounds and methods for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning. Preferably, the composition of bio-active compounds includes a combination of 4-hydroxyisoleucine with at least one amino acid selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, lysine, histidine, gamma-amino butyrate and tyrosine. In one presently preferred embodiment of the present invention, the combination is derived, isolated, and/or extracted from fenugreek seeds. Methods for using a novel composition of bio-active compounds from fenugreek seed for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning are also disclosed, wherein methods comprise the steps of: (1) providing an effective amount of a composition of bio-active compounds derived, isolated, and/or extracted from fenugreek seeds; and (2) administering the composition to a human or animal.

Provided are compositions and methods for increasing diet induced thermogenesis. Typically, the compositions are comprised of L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-valine and L-threonine.

The invention relates to polynucleotides comprising polynucleotide sequences corresponding to the metD gene and parts thereof that encode polypeptide sequences and parts thereof possessing varying degrees of MetD transcription regulator activity, methods for preparation of L-amino acids, and methods of screening and amplifying polynucleotides encoding polypeptide sequences which comprise varying degrees of MetD transcription regulator activity. Further, the invention relates to animal food additives based on fermentation liquor and containing L-methionine, and to the preparation of such additive.

Methods are provided for detecting methionine aminopeptidase (MAP) activity and for detecting inhibitors of MAP. The methods utilize a peptide comprising an N-terminal methionine which can be cleaved from the peptide by MAP, and a C-terminal detection moiety which is released by a second peptidase only if the N-terminal methionine has been cleaved from the peptide. When the peptide is combined with MAP and the second peptidase, the detection moiety is released, while the addition of a MAP inhibitor will inhibit the release of the detection moiety. Reaction mixes, peptides, and kits which are useful for practicing the methods are also provided.

Compositions of S-adenosyl-L-methionine with additives are disclosed.

The present invention discloses a feed for promoting sows aphrodisiac and more farrowing, which belongs to the technical field of pig feed. The feed comprises the components as the weight of 600 to 700 shares of corn, 220 to 280 shares of soybean meal, 20 to 50 shares of corn gluten meal, 20 to 50 shares of fish meal, 10 to 30 shares of soybean oil, 5 to 15 shares of dicalcium phosphate, 10 to 20 shares of rock powder, 3 to 5 shares of salt, 2 to 4 shares of lysine, 0.2 to 0.5 shares of methionine, 0.2 to 0.5 shares of threonine, 2 to 4 shares of minerals vitamin and 5 to 15shares of additives. The sows can definitely have more than four kilograms daily meal after weaning with the feed and feeding about six days, the main function of the present invention is to early estrus, and more litter. Using the feed can make sow early estrus and more litter, and strengthen the needs of nutrition for sows breeding, supplement the iron and zinc trace elements, and enhance the ability of the breeding sows.

The invention discloses an organic selenium biologics and its preparation method, and method for producing selenium-rich vegetable using the same, wherein the preparation is prepared from water and the following components (by weight percentage) through mixing and fermentation, selenium dioxide : sodium hydrogen carbonate : methionine : brown sugar : carbamide : monobasic potassium phosphate : magnesium sulfate : manganese sulfate : calcium chloride = 35-45 : 35-45 : 10-20 : 45-55 : 1-10 : 1-10 : 1-4 : 1-4 : 1-10, the method of application comprises, diluting the organic selenium biologics to 50-200 times by charging water, spraying diluted organic selenium biologics liquid onto the vegetable leaves, stems or roots. The vegetable exerted by the organic selenium biologics contains rich selenium.

The subject invention relates to the cloning, expression and isolation of recombinant forms of beta-amyloid protein containing a N-terminal methionine (or one or more amino acids) as well as to methods of using this recombinant protein in the production of therapeutic antibodies, in the identification of therapeutic small molecules, and in the performance of diagnostic assays.

The present invention relates to the use of recombinant homoserine transsuccinylase enzymes with altered feedback sensitivity (MetA*) and possibly recombinant S-adenosyl methionine synthetase enzymes with reduced activity (MetK*) for the production of methionine, its precursors or derivatives thereof.